GSK (LON:GSK – Get Free Report)‘s stock had its “sector perform” rating reaffirmed by Royal Bank Of Canada in a research report issued to clients and investors on Tuesday, Digital Look reports. They currently have a GBX 1,975 target price on the stock. Royal Bank Of Canada’s target price would indicate a potential upside of 9.57% from the company’s current price.
Several other equities analysts have also issued reports on GSK. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 2,000 price objective on shares of GSK in a research report on Wednesday, September 2nd. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a report on Wednesday, July 29th. Two investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of GBX 2,039.38.
Check Out Our Latest Stock Report on GSK
GSK Stock Up 0.3%
GSK (LON:GSK – Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. As a group, equities analysts expect that GSK will post 175.980975 earnings per share for the current year.
Insiders Place Their Bets
In other news, insider Jeannie Lee purchased 802 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was purchased at an average price of GBX 5,069 per share, for a total transaction of £40,653.38. Also, insider Jonathan Symonds purchased 1,550 shares of the business’s stock in a transaction on Friday, June 19th. The stock was purchased at an average price of GBX 1,935 per share, with a total value of £29,992.50. Over the last three months, insiders have bought 3,618 shares of company stock valued at $13,481,942. 0.20% of the stock is currently owned by corporate insiders.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Featured Stories
- Five stocks we like better than GSK
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
